Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690054 | 0.87 | ERN1 (0.43) | ERN1ALDH1A1HPGDMAPTPTGS2 | |
| SCHEMBL289510 | 0.83 | CTSL (0.43) | ERN1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3851503 | 0.80 | NQO1 (0.45) | ERN1ALDH1A1HPGDMAPTFFAR1 | |
| SCHEMBL14690141 | 0.79 | FFAR4 (0.44) | ERN1ALDH1A1HPGDMAPTPTGS2 | |
| SCHEMBL10388263 | 0.78 | NQO1 (0.54) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL3170130 | 0.77 | NQO1 (0.45) | ERN1ALDH1A1HPGDKMT2AMAPT | |
| SCHEMBL16616316 | 0.76 | LMNA (0.48) | POLBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9228732 | 0.75 | NQO1 (0.48) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL16616017 | 0.75 | PIM1 (0.42) | ERN1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL18570379 | 0.72 | CACNA1C (0.50) | ERN1ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571356-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2011146324-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | ERN1 2810/4885POLB 3584/4885ALDH1A1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.